Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Sponsor

Celgene (Industry)

Overall Status

Completed

CT.gov ID

NCT00179608

Collaborator

Prologue Research International (Industry)

Enrollment

Location

Actual Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy. This study will evaluate the safety and preliminary efficacy of the combination of lenalidomide and DTIC. Subjects will be receive lenalidomide for 14 consecutive days and DTIC on day one of each 21 day cycle.

Condition or Disease	Intervention/Treatment	Phase
Malignant Melanoma	Drug: CC-5013	Phase 1

Study Design

Study Type:

Interventional

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Actual Study Start Date :

Sep 1, 2005

Actual Primary Completion Date :

Jun 1, 2007

Actual Study Completion Date :

Jun 1, 2007

Outcome Measures

Primary Outcome Measures

To determine MTD of intravenous DTIC during the first 2 cycles (6 wks) of treatment []

Secondary Outcome Measures

To evaluate the safety profile of combination lenalidomide plus DTIC, the preliminary efficacy of combination lenalidomide plus DTIC []
To define the recommended phase II doses of lenalidomide and DTIC when administered as combination therapy. []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Understand and voluntarily sign an informed consent document
Age greater than or equal to 18 years at the time of signing Informed Consent
Be able to adhere to the study visit schedule and other protocol requirements
Histological documentation of malignant melanoma with evidence of metastatic disease
For the 10 patients enrolled at the MTD, at least one measurable lesion must be present (see Appendix II)
ECOG performance status of 0, 1 or 2 (see Appendix I)
Laboratory tests within these ranges:
Absolute neutrophil count greater than or equal to 1,500/uL
Platelet count greater than or equal to 100,000/uL
Serum creatinine less than or equal to 1.5 mg/dL
Total bilirubin less that or equal to 1.5 mg.dL
AST (SGOT) / ALT (SGPT) less than or equal to to 2 times upper limit of normal (ULN)
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.

In addition, sexually active WCBP must agree to use at least two methods of adequate contraceptive (oral, injectable, or implantable hormonal contraceptive, tubal ligation, intra-uterine device, barrier contraceptive with spermicide, contraceptive skin patch or vasectomized partner) while on study drug

All acute adverse effects (excluding alopecia of any prior therapy must have resolved to less than or equal to grade 1 (NCI CTCAE v3.0)
Patients must be able to take medications orally

Exclusion Criteria:

Pregnant or lactating females
Any serious medical condition, including psychiatric illnesses that will prevent the patient from signing the informed consent or place the patient at an unacceptable risk if he/she participates in the study.
Prior treatment with systemic chemotherapy. Patients who have received prior immunotherapy, including thalidomide, or radiotherapy remain eligible.

Lesions within a prior field of radiation may only be used as indicator lesions if there has been evidence of disease progression at that site.

Prior history of malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been free of the disease for at least 3 years.
Use of thalidomide or biologic response modifier therapy within 14 days of Day 1, Cycle 1
Prior greater than or equal to grade 2 allergic reaction to thalidomide
Prior desquamating rash while taking thalidomide
Any prior use of lenalidomide
Concurrent use of any other anti-cancer agents
Radiation or surgical treatment of melanoma within 28 days of starting study treatment
Active infection
Central nervous system (CNS) metastases
Patients with > grade-2 neuropathy
Patients with known HIV positivity or AIDS-related illness